Elsevier and Russian Foundation of Basic Research Sign SciVerse ScienceDirect Access Agreement

150 Russian research institutes involved in long-term collaboration

Amsterdam, February 1, 2012 - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced it has reached an agreement with the Russian Foundation of Basic Research (RFBR) to provide 150 Russian research institutes with access to SciVerse ScienceDirect as well as trial access to SciVerse Scopus. This one-year license agreement is part of a formal collaboration program between Elsevier and RFBR until 2014.

Academician Prof. Vladislav Panchenko, Chairman of the RFBR Board, said of the agreement, “Access to up-to-date scientific information is a necessary element for researchers in their workflow. That is why we are glad to see us collaborate so closely with Elsevier, providing our scientists with access to a quarter of the world’s scientific research. We are happy for this continuous and mutually beneficial cooperation. We hope that together we will drive Russian science to the top of global scientific scene.”

Igor Osipov, PhD, Elsevier Regional Director for Russia and Belarus added, “RFBR and its leadership has become a true partner to us – we organize joint events, run training programs across the country and strive to support and reward Russian researchers with the best available content and solutions. With this new agreement, our joint work in bringing best Russian science to the international arena and supporting Russian government efforts in building better and efficient research shall be continued in the years to come.”

# # #

About the Russian Foundation for Basic Research
The Russian Foundation for Basic Research is a self-governing foundation existing in the form of a federal institution run under the jurisdiction of the government of the Russian Federation. Its main goal is to provide support and assistance to research work in all areas of fundamental science on a competitive basis and which is called upon to build new relationships between scientists and the state. The foundation distributes federal funding to the most advanced research projects originating both from Russian universities as well as from institutions of the Russian Academy of Sciences. The RFBR is part of G8 scientific foundations family and enjoys close cooperation ties with all key funding bodies across the globe: from North America to EU, China and Japan. Financing refereed projects across disciplines, key attention is given to physics, technology and nano-technology, medicine, various interdisciplinary studies, which Russian government identified as priority in R&D development until 2020.

About the Elsevier SciVerse Suite
The SciVerse® suite of search and discovery offerings provides the global research community access to a constantly expanding universe of content and solutions which can now be accessed in one platform. The suite currently includes SciVerse ScienceDirect®, the world’s largest source of peer-reviewed content containing more than 10 million articles, and  SciVerse Scopus®, an abstract and citation database containing 41 million records, 70% with abstracts and nearly 19,500 titles from 5,000 publishers worldwide. The platform also includes  SciVerse Hub which enables researchers to perform a single search across all of the SciVerse content as well as targeted web content with results ranked by relevancy and without duplication.  Applications and  Developer Network allow the scientific community to build, find and use applications that enhance the SciVerse research experience.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Galina Yakshonak
Elsevier, Russia
+7 985 72 779 67
g.yakshonak@elsevier.com